Guerbet SA (EPA:GBT)

Market Cap	221.28M
Revenue (ttm)	820.92M
Net Income (ttm)	7.74M
Shares Out	12.60M
EPS (ttm)	0.61
PE Ratio	28.60
Forward PE	18.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,128
Average Volume	11,029
Open	18.00
Previous Close	18.02
Day's Range	17.56 - 18.04
52-Week Range	12.72 - 28.70
Beta	0.81
RSI	66.04
Earnings Date	Mar 11, 2026

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1926
• Employees: 2,905
• Stock Exchange: Euronext Paris
• Ticker Symbol: GBT

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.